Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Annals of Oncology Podcasts

Listen to the most recent Podcasts developed by Annals of Oncology.


Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer

Article of the Month series

Annals of Oncology Editor-in-Chief Tom Powles talks to Dr Giorgio Bogani, of the Istituto Nazionale dei Tumori di Milano, Italy. They discuss the recently published study considering recent phase III trials that investigated the role of immunotherapy in the first-line setting for advanced or recurrent endometrial cancer.

Bogani G, Monk BJ, Powell MA, et al. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer. Ann Oncol. 2024;35(5):414-428.
DOI: https://doi.org/10.1016/j.annonc.2024.02.006

Published in May 2024


B-cell infiltration is associated with survival following PD-1 inhibition in HNSCC

Article of the Month series

Annals of Oncology Editor in Chief Tom Powles talks to Prof. Amanda Psyrri, of the National Kapodistrian University of Athens, Greece. They discuss her recently published study that aimed to investigate the association of immune cell-related biomarkers in the tumor and tumor microenvironment with PD-1 checkpoint inhibitors’ outcomes in patients with metastatic head and neck squamous cell cancer (HNSCC).

Gavrielatou N, Fortis E, Spathis A, et al. B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma. Ann Oncol. 2024;35(4):340-350.
DOI: https://doi.org/10.1016/j.annonc.2023.12.011

Published in April 2024


Response-guided neoadjuvant sacituzumab govitecan for localized TNBC

Article of the Month series

Sacituzumab govitecan (SG), a novel antibody–drug conjugate (ADC) targeting TROP2, is approved for pre-treated metastatic triple-negative breast cancer (mTNBC). In this podcast, Annals of Oncology Editor-in-Chief Prof. Tom Powles, discusses with Prof. Aditya Bardia the NeoSTAR trial, the subject of Annals of Oncology's article of the month for March, an investigator-initiated clinical trial evaluating neoadjuvant (NA) SG for localized TNBC.

L. M. Spring, S. M. Tolaney, G. Fell, et al. Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. Annals of Oncology. 2024;35(3):293-301.
DOI: https://doi.org/10.1016/j.annonc.2023.11.018

Published in March 2024


ctDNA and radiological tumor volume and risk of relapse with resected, early-stage NSCLC

Article of the Month series

Predicting relapse and overall survival (OS) in early-stage non-small-cell lung cancer (NSCLC) patients remains challenging. In this podcast, Professor John Heymach, University of Texas MD Anderson Cancer Center, Huston, USA, discusses, with Annals of Oncology Editor-in-Chief, Tom Powles, a study in which serial plasma samples from early-stage NSCL patients who underwent surgical resections were analysed and ctDNA assessed using a next-generation sequencing liquid biopsy assay, and tumor volume measured using a computed tomography-based three-dimensional annotation to assess risk.

Tran HT, Heeke S, Sujit S, et al. Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer. Annals of Oncology. 2024;35(2):183-189.
DOI: doi.org/10.1016/j.annonc.2023.11.008

Published in February 2024


The DAD trial: sacituzumab govitecan+enfortumab vedotin for metastatic urothelial carcinoma

Article of the Month series

Dr Brad McGregor, of the Dana Farber Cancer Institute, discusses the DAD phase I trial with Annals of Oncology Editor-in-Chief, Prof. Tom Powles. This is the first trial in any malignancy to show that antibody-drug conjugates could be safely given in combination.

McGregor BA, Sonpavde GP, Kwak L et al. The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. Ann Oncol 2023; 35: 91-97.
DOI: https://doi.org/10.1016/j.annonc.2023.09.3114

Published in January 2024


Genome instability and success of checkpoint inhibitors

Dr Sarah Derks, of Amsterdam UMC, discusses her recent editorial in Annals of Oncology on the report of Shitara et al. who presented an exploratory analysis from the KEYNOTE-061 trial evaluating the association of tTMB with PD-L1 and MSI-H and their relationship with clinical outcomes in patients with advanced gastric/GEJ cancer receiving second-line pembrolizumab or paclitaxel.

Derks S. Genome instability and success of checkpoint inhibitors: form and levels matter. Ann Oncol 2021; 32: 1073-1074.
Shitara K et al. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. Ann Oncol 2021; 32: 1127-1136.

Published in September 2021


Immunotherapy trials for metastatic triple-negative breast cancer

Dr Marleen Kok, of the Netherlands Cancer Institute, discusses her recent editorial, written with Dr Leonie Voorwerk, on the results of the IMpassion130 and IMpassion131 trials of immunotherapy in unresectable, locally advanced, or metastatic triple-negative breast cancer, results of which are both published in the August issue of Annals of Oncology.

Voorwerk L, Kok M. ‘IMpassionate conflicts’ in immunotherapy trials for metastatic triple-negative breast cancer. Ann Oncol 2021; 32: 947-949.

Published in September 2021


IgE blockade in the management of eosinophil-associated recalcitrant pruritus

Professor Ralf Gutzmer, of the Skin Cancer Center Minden, discusss his recent editorial, with colleagues, on a the recently published study of Barrios et al, which sought to evaluate the efficacy and safety of IgE blockade with omalizumab in cancer patients with refractory pruritus-associated cutaneous adverse events related to checkpoint inhibitors and anti-HER2 agents.

Gutzmer R, Sibaud V, Hassel JC. IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy. Ann Oncol 2021; 32: 696-697.
Barrios DM, Phillips GS, Geisler AN et al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol 2021; 32: 736-745.

Published in July 2021


Cabazitaxel vs abiraterone or enzalutamide in poor prognosis metastatic CRPC

Professor Ronald de Wit, of the Erasmus MC Cancer Institute, Rotterdam, discusses the editorial he wrote with colleagues on the recent publication of Annala et al.They reported on a randomised, phase II study evaluating cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer.

Annala M, Fu S, Bacon JVW et al. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Ann Oncol 2021; 32: 896-905.
Robbrecht DHJ, Buck SAJ, de Wit R. Outcomes of treatment choices in poor prognosis prostate cancer: notagainst all odds. Ann Oncol 2021; 32: 831-832.

Published in July 2021


This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.